Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has ended one of biopharma's most closely watched leadership searches. On August 3, the Mainz-based mRNA company announced that its Supervisory Board had selected Guido Oelkers, Ph.D., currently CEO of Stockholm-listed Swedish Orphan Biovitrum (Sobi), as its next Chief Executive Officer, according to a company press release distributed via GlobeNewswire. Oelkers is expected to take office no later than February 1, 2027.

The appointment resolves a vacancy that had been open for roughly five months. In March 2026, co-founders Ugur Sahin and Chief Medical Officer Özlem Türeci disclosed plans to exit BioNTech together and launch a new venture centered on next-generation mRNA innovations, as Fierce Biotech reported at the time. Sahin will remain actively involved through the transition to support Oelkers's onboarding, according to the company.

A revenue-scaling track record that clinched the role

Oelkers brings more than 30 years in biotechnology and pharmaceuticals, with a biography that spans CEO roles at publicly traded and private-equity-backed companies across Europe and the Asia-Pacific region. His tenure at Sobi, which began in 2017, is the credential BioNTech's board appears to have weighted most heavily: over his nine-year run, he more than quadrupled the company's revenues, according to BioNTech's official announcement.

At Sobi, Oelkers oversaw the licensing of AstraZeneca's respiratory syncytial virus therapy Synagis, the $915 million acquisition of Dova Pharmaceuticals for the thrombocytopenia drug Doptelet, and the launch of the bleeding-disorder treatment Altuviiio in partnership with Sanofi, Fierce Biotech reported. That deal-making and commercial-execution record maps directly onto what BioNTech needs: converting a mature pipeline into approved, revenue-generating products.

Before Sobi, Oelkers led BSN Medical Holding GmbH as CEO and served as President and CEO of Swedish medtech company Gambro AB, as well as CEO of specialty pharma firm Invida Holdings. Earlier executive roles included positions at Nycomed, DKSH Group, Aventis Pharma China, and Hoechst, where he started his career, according to BioNTech's biographical disclosure.

What Oelkers inherits: a pipeline under active development

BioNTech rose to global prominence through its Pfizer partnership on the COVID-19 vaccine Comirnaty, but the company's current strategic identity is built around oncology. Fierce Biotech noted that BioNTech has been describing 2026 as a "catalyst-rich year," with phase 3 readouts anticipated for several candidates.

The most advanced near-term asset is trastuzumab pamirtecan, an HER2-targeted antibody-drug conjugate licensed from China's DualityBio, which is progressing toward a potential approval filing. The portfolio also includes gotistobart, an anti-CTLA-4 antibody developed in partnership with OncoC4, and pumitamig, a PD-L1xVEGF-A bispecific immunomodulator co-developed with Bristol Myers Squibb that showed encouraging anti-tumor activity in non-small cell lung cancer data released earlier this year, according to Fierce Biotech.

Oelkers described BioNTech's scientific foundation and late-stage oncology pipeline as the company's distinguishing characteristic in a statement carried in the GlobeNewswire release. His stated priority is advancing that pipeline toward multiple approvals by 2030 while continuing to build out pre-clinical and clinical programs aligned with the company's patient-centric strategy.

Leadership structure still taking shape

The CEO appointment is one part of a broader management realignment. BioNTech confirmed that the search for a new Chief Medical Officer to succeed Türeci remains ongoing. The company said it is looking for a candidate with deep expertise in late-stage clinical development and a track record with complex, innovative product candidates, according to the official announcement.

Supervisory Board Chairman Helmut Jeggle framed Oelkers's appointment in explicitly commercial terms, pointing to his ability to translate scientific output into commercial success and to scale innovation-driven organizations in a capital-efficient manner, as quoted in BioNTech's press release. The emphasis on capital efficiency is notable: BioNTech has been operating in a post-COVID revenue environment that requires disciplined prioritization across a broad pipeline.

The leadership transition means BioNTech will enter the critical 2027 approval windows with a new CEO, a new CMO still to be named, and the co-founders shifted to a separate enterprise. For enterprise partners evaluating collaboration agreements, licensing discussions, or supply-chain commitments with BioNTech, the period between now and Oelkers's start date will be one to monitor closely.